<!doctype html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Valvular Heart Disease - Clinical Study Note</title>
    <link rel="icon" type="image/png" sizes="48x48" href="/icons/favicon-48.png?v=20260227-favicon1" />
    <link rel="icon" type="image/png" sizes="32x32" href="/icons/favicon-32.png?v=20260227-favicon1" />
    <link rel="icon" type="image/png" sizes="16x16" href="/icons/favicon-16.png?v=20260227-favicon1" />
    <link rel="apple-touch-icon" sizes="180x180" href="/icons/favicon-180.png?v=20260227-favicon1" />
    <style>
      :root {
        --bg: #f8fbff;
        --surface: #ffffff;
        --ink: #132741;
        --muted: #546a82;
        --line: #d7e3f0;
        --brand: #8a1f4d;
        --brand-soft: #fff0f7;
        --teal-soft: #edf9f7;
        --warn-soft: #fff6e8;
        --danger-soft: #fff0f0;
      }

      * {
        box-sizing: border-box;
      }

      body {
        margin: 0;
        font-family: "Segoe UI", Tahoma, Arial, sans-serif;
        color: var(--ink);
        background:
          radial-gradient(circle at 86% 7%, #ffd9e9 0%, transparent 30%),
          radial-gradient(circle at 10% 20%, #e0f3ff 0%, transparent 25%),
          var(--bg);
      }

      .wrap {
        width: min(1240px, 94vw);
        margin: 22px auto 34px;
        display: grid;
        grid-template-columns: 290px 1fr;
        gap: 16px;
      }

      .panel {
        background: var(--surface);
        border: 1px solid var(--line);
        border-radius: 16px;
        box-shadow: 0 10px 24px rgba(13, 34, 62, 0.06);
      }

      .toc {
        position: sticky;
        top: 16px;
        max-height: calc(100dvh - 32px);
        overflow: auto;
        padding: 14px;
      }

      .toc h2 {
        margin: 0 0 10px;
        color: var(--brand);
        font-size: 1rem;
      }

      .toc a {
        display: block;
        text-decoration: none;
        color: #354a64;
        border-radius: 8px;
        padding: 7px 9px;
        font-size: 13px;
      }

      .toc a:hover {
        background: #fff2f8;
        color: #70213f;
      }

      .content {
        padding: 0 0 18px;
      }

      .hero {
        padding: 20px;
        border-bottom: 1px solid var(--line);
        background: linear-gradient(
          160deg,
          #fffdfd 0%,
          #fff2f8 56%,
          #edf9f7 100%
        );
      }

      .eyebrow {
        display: inline-flex;
        align-items: center;
        min-height: 28px;
        padding: 5px 12px;
        border-radius: 999px;
        background: var(--brand-soft);
        color: #8a1f4d;
        font-size: 12px;
        font-weight: 700;
        margin-bottom: 10px;
      }

      h1 {
        margin: 0;
        color: #691a39;
        font-size: clamp(1.42rem, 2.4vw, 2.04rem);
      }

      .subtitle {
        margin: 8px 0 0;
        color: var(--muted);
        line-height: 1.55;
      }

      .hero-layout {
        margin-top: 14px;
        display: grid;
        grid-template-columns: 1.35fr 0.95fr;
        gap: 12px;
      }

      .hero-grid {
        display: grid;
        grid-template-columns: repeat(4, minmax(0, 1fr));
        gap: 10px;
      }

      .metric {
        border: 1px solid #f0d4e2;
        border-radius: 12px;
        background: #fff;
        padding: 10px;
      }

      .metric .k {
        font-size: 11px;
        color: #7c5a6a;
        margin-bottom: 6px;
        text-transform: uppercase;
        letter-spacing: 0.3px;
      }

      .metric .v {
        font-size: 14px;
        color: #671938;
        font-weight: 700;
      }

      .hero-visual {
        border: 1px solid #efcfdd;
        border-radius: 14px;
        background: #fff;
        padding: 10px;
        display: grid;
        gap: 8px;
      }

      .hero-visual h3 {
        margin: 0;
        font-size: 0.95rem;
        color: #6e1f40;
      }

      .hero-visual p {
        margin: 0;
        font-size: 0.84rem;
        color: #5d758c;
      }

      .hero-visual svg {
        width: 100%;
        height: auto;
        display: block;
      }

      .section {
        padding: 16px 20px;
        border-bottom: 1px solid #edf3fb;
      }

      .section:last-child {
        border-bottom: none;
      }

      .section h2 {
        margin: 0 0 10px;
        color: #6d1f40;
        font-size: 1.16rem;
      }

      .section p {
        margin: 0;
        color: #314860;
        line-height: 1.56;
      }

      .stack {
        margin-top: 10px;
        display: grid;
        gap: 10px;
      }

      .grid-2 {
        display: grid;
        grid-template-columns: repeat(2, minmax(0, 1fr));
        gap: 10px;
      }

      .grid-3 {
        display: grid;
        grid-template-columns: repeat(3, minmax(0, 1fr));
        gap: 10px;
      }

      .box {
        border: 1px solid var(--line);
        border-radius: 12px;
        padding: 11px 12px;
        background: #fff;
      }

      .box h3 {
        margin: 0 0 7px;
        font-size: 0.97rem;
        color: #1f4061;
      }

      .box p {
        margin: 0;
      }

      .box ul {
        margin: 0 0 0 17px;
        padding: 0;
      }

      .box li {
        margin: 4px 0;
        color: #304860;
      }

      .table {
        margin-top: 8px;
        width: 100%;
        border-collapse: collapse;
        border-radius: 12px;
        border: 1px solid var(--line);
        overflow: hidden;
      }

      .table th,
      .table td {
        padding: 10px;
        text-align: left;
        font-size: 14px;
        border-bottom: 1px solid #e8eff8;
        vertical-align: top;
      }

      .table th {
        background: #fff3f8;
        color: #6e1f40;
      }

      .table tr:last-child td {
        border-bottom: none;
      }

      .chips {
        margin-top: 8px;
        display: flex;
        gap: 8px;
        flex-wrap: wrap;
      }

      .chip {
        display: inline-flex;
        align-items: center;
        min-height: 30px;
        padding: 4px 10px;
        border-radius: 999px;
        border: 1px solid #d8e4f2;
        background: #f8fbff;
        color: #254764;
        font-size: 13px;
        font-weight: 600;
      }

      .callout {
        margin-top: 10px;
        border-left: 4px solid #0f766e;
        border-radius: 10px;
        background: var(--teal-soft);
        color: #175358;
        padding: 10px 12px;
      }

      .callout.warn {
        border-left-color: #b66a00;
        background: var(--warn-soft);
        color: #7c5b1d;
      }

      .callout.alert {
        border-left-color: #b91c1c;
        background: var(--danger-soft);
        color: #6d2222;
      }

      .flow {
        margin-top: 10px;
        display: grid;
        gap: 9px;
      }

      .step {
        border: 1px solid #d5e3f4;
        border-radius: 12px;
        padding: 10px 11px;
        background: #f9fcff;
      }

      .step strong {
        color: #6d1f40;
      }

      .arrow {
        width: 30px;
        height: 30px;
        margin: 0 auto;
        border-radius: 999px;
        border: 1px solid #c9d8ec;
        background: #f6fbff;
        color: #456887;
        font-weight: 900;
        display: grid;
        place-items: center;
        line-height: 1;
      }

      .diagram-card {
        margin-top: 10px;
        border: 1px solid #d8e4f2;
        border-radius: 12px;
        background: #fbfdff;
        padding: 11px;
      }

      .diagram-title {
        margin: 0 0 8px;
        font-size: 0.9rem;
        color: #1d3f62;
        font-weight: 700;
      }

      .refs a {
        color: #145aa9;
        text-decoration: none;
        word-break: break-word;
      }

      .refs a:hover {
        text-decoration: underline;
      }

      @media (max-width: 1040px) {
        .wrap {
          grid-template-columns: 1fr;
        }

        .toc {
          position: static;
          max-height: none;
        }

        .hero-layout {
          grid-template-columns: 1fr;
        }

        .hero-grid {
          grid-template-columns: repeat(2, minmax(0, 1fr));
        }
      }

      @media (max-width: 760px) {
        .grid-2,
        .grid-3,
        .hero-grid {
          grid-template-columns: 1fr;
        }
      }
    </style>
  </head>
  <body>
    <div class="wrap">
      <aside class="panel toc">
        <h2>On This Page</h2>
        <a href="#what-is-vhd">1. What Is Valvular Heart Disease?</a>
        <a href="#major-valve-disorders">2. Major Valve Disorders</a>
        <a href="#aortic-stenosis">3. Aortic Stenosis</a>
        <a href="#aortic-regurgitation">4. Aortic Regurgitation</a>
        <a href="#mitral-regurgitation">5. Mitral Regurgitation</a>
        <a href="#mitral-stenosis">6. Mitral Stenosis</a>
        <a href="#prosthetic-valves">7. Prosthetic Valves</a>
        <a href="#endocarditis-prophylaxis">8. Endocarditis Prophylaxis</a>
        <a href="#management-recap-drill">Recap Drill</a>
        <a href="#exam-traps">9. Common Exam Traps</a>
        <a href="#quick-revision">10. Quick Revision Summary</a>
      </aside>

      <article class="panel content">
        <header class="hero">
          <span class="eyebrow">Cardiovascular Disorders</span>
          <h1>Valvular Heart Disease</h1>
          <p class="subtitle">
            Clinical overview and exam mastery guide covering aortic and mitral
            valve disease, drug support strategies, intervention timing, and
            prosthetic valve anticoagulation.
          </p>

          <div class="hero-layout">
            <div class="hero-grid">
              <div class="metric">
                <div class="k">Core Lesions</div>
                <div class="v">Stenosis or regurgitation</div>
              </div>
              <div class="metric">
                <div class="k">High-Yield Valves</div>
                <div class="v">Aortic and mitral</div>
              </div>
              <div class="metric">
                <div class="k">Severe AS Clue</div>
                <div class="v">SAD triad</div>
              </div>
              <div class="metric">
                <div class="k">Mechanical Valve</div>
                <div class="v">Warfarin required</div>
              </div>
            </div>

            <div class="hero-visual">
              <h3>Valve Lesion Pattern</h3>
              <svg viewBox="0 0 500 220" role="img" aria-label="Valvular lesions diagram">
                <rect x="0" y="0" width="500" height="220" rx="14" fill="#fbfdff" />
                <rect x="20" y="35" width="205" height="66" rx="10" fill="#fff2f8" stroke="#f0d3e0" />
                <text x="42" y="60" fill="#7a2047" font-size="13" font-weight="700">Stenosis</text>
                <text x="42" y="80" fill="#7b5b6a" font-size="12">Narrow orifice -> pressure overload</text>
                <rect x="275" y="35" width="205" height="66" rx="10" fill="#eef7ff" stroke="#d8e6f6" />
                <text x="297" y="60" fill="#214766" font-size="13" font-weight="700">Regurgitation</text>
                <text x="297" y="80" fill="#59748e" font-size="12">Backflow -> volume overload</text>
                <path d="M225 68H275" stroke="#9bb6d2" stroke-width="2.2" marker-end="url(#arr)" />

                <rect x="20" y="130" width="460" height="66" rx="10" fill="#ffffff" stroke="#d8e4f2" />
                <text x="42" y="156" fill="#294761" font-size="13" font-weight="700">Definitive strategy in severe disease</text>
                <text x="42" y="174" fill="#45637e" font-size="12">Surgical replacement/repair or transcatheter intervention (selected patients)</text>
                <defs>
                  <marker id="arr" markerWidth="6" markerHeight="6" refX="5" refY="3" orient="auto">
                    <path d="M0,0 L6,3 L0,6 Z" fill="#9bb6d2"></path>
                  </marker>
                </defs>
              </svg>
              <p>Medical therapy supports symptoms; intervention is definitive in advanced lesions.</p>
            </div>
          </div>
        </header>

        <section class="section" id="what-is-vhd">
          <h2>1. What Is Valvular Heart Disease?</h2>
          <p>
            Valvular heart disease (VHD) is dysfunction of one or more cardiac
            valves resulting in stenosis (narrowing) or regurgitation
            (backflow). The most tested lesions involve aortic and mitral valves.
          </p>
          <div class="chips">
            <span class="chip">Aortic valve</span>
            <span class="chip">Mitral valve</span>
            <span class="chip">Stenosis</span>
            <span class="chip">Regurgitation</span>
          </div>
        </section>

        <section class="section" id="major-valve-disorders">
          <h2>2. Major Valve Disorders</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Aortic Lesions</h3>
              <ul>
                <li>Aortic stenosis (AS)</li>
                <li>Aortic regurgitation (AR)</li>
              </ul>
            </div>
            <div class="box">
              <h3>Mitral Lesions</h3>
              <ul>
                <li>Mitral regurgitation (MR)</li>
                <li>Mitral stenosis (MS)</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="aortic-stenosis">
          <h2>3. Aortic Stenosis (AS)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Pathophysiology</h3>
              <ul>
                <li>Calcific degeneration or congenital bicuspid valve</li>
                <li>LV outflow obstruction and increased afterload</li>
                <li>Left ventricular hypertrophy</li>
              </ul>
            </div>
            <div class="box">
              <h3>Classic Symptoms</h3>
              <ul>
                <li>Syncope</li>
                <li>Angina</li>
                <li>Dyspnea (heart failure)</li>
              </ul>
              <p><strong>SAD</strong> is the classic severe AS triad.</p>
            </div>
          </div>
          <div class="callout warn">
            Definitive treatment is valve replacement (surgical AVR or TAVR in
            selected patients). Drugs are supportive and do not reverse severe AS.
          </div>
          <div class="callout alert">
            Avoid aggressive vasodilation in severe aortic stenosis.
          </div>
        </section>

        <section class="section" id="aortic-regurgitation">
          <h2>4. Aortic Regurgitation (AR)</h2>
          <p>
            Incomplete valve closure causes diastolic backflow into the LV,
            leading to chronic volume overload and LV dilation.
          </p>
          <table class="table">
            <thead>
              <tr>
                <th>Therapy</th>
                <th>MOA</th>
                <th>Side Effects</th>
                <th>Contraindications</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>ACE inhibitors</td>
                <td>Reduce angiotensin II and systemic vascular resistance (afterload reduction)</td>
                <td>Cough, hyperkalemia, renal impairment</td>
                <td>Pregnancy, bilateral renal artery stenosis</td>
              </tr>
            </tbody>
          </table>
          <div class="callout">
            Definitive treatment is valve replacement when symptomatic or with LV dysfunction.
          </div>
        </section>

        <section class="section" id="mitral-regurgitation">
          <h2>5. Mitral Regurgitation (MR)</h2>
          <p>
            Backflow into the left atrium causes volume overload, left atrial
            enlargement, and increased risk of atrial fibrillation.
          </p>
          <div class="stack">
            <div class="box">
              <h3>Management Priorities</h3>
              <ul>
                <li>Valve repair is preferred for suitable symptomatic patients</li>
                <li>Afterload reduction support (e.g., ACE inhibitors)</li>
                <li>Diuretics for congestion symptom control</li>
              </ul>
            </div>
            <div class="box">
              <h3>Loop Diuretics</h3>
              <ul>
                <li>MOA: inhibit Na-K-2Cl transporter in loop of Henle</li>
                <li>Effect: reduce volume overload symptoms</li>
                <li>Side effects: hypokalemia, dehydration, hypotension</li>
                <li>Role: symptom control only (not definitive lesion correction)</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="mitral-stenosis">
          <h2>6. Mitral Stenosis (MS)</h2>
          <p>
            Often rheumatic in origin. Obstructed LV filling raises left atrial
            pressure, causes pulmonary congestion, and increases AF/thromboembolic risk.
          </p>
          <div class="grid-2">
            <div class="box">
              <h3>Beta Blockers</h3>
              <ul>
                <li>MOA: slow heart rate and increase diastolic filling time</li>
                <li>Side effects: bradycardia, fatigue</li>
              </ul>
            </div>
            <div class="box">
              <h3>Anticoagulation (If AF)</h3>
              <ul>
                <li>Warfarin preferred in rheumatic MS with AF</li>
                <li>Goal: reduce systemic embolic stroke risk</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="prosthetic-valves">
          <h2>7. Prosthetic Valves</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Mechanical Valves</h3>
              <ul>
                <li>Durable option</li>
                <li>Requires lifelong warfarin anticoagulation</li>
              </ul>
            </div>
            <div class="box">
              <h3>Bioprosthetic Valves</h3>
              <ul>
                <li>Less durable</li>
                <li>Shorter anticoagulation duration in many cases</li>
              </ul>
            </div>
          </div>
          <table class="table">
            <thead>
              <tr>
                <th>Drug</th>
                <th>MOA</th>
                <th>Monitoring</th>
                <th>Contraindications / Traps</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Warfarin (mechanical valve)</td>
                <td>Inhibits vitamin K-dependent factors II, VII, IX, X</td>
                <td>INR typically 2.5 to 3.5 (valve dependent)</td>
                <td>Pregnancy contraindication; DOACs contraindicated in mechanical valves</td>
              </tr>
            </tbody>
          </table>
        </section>

        <section class="section" id="endocarditis-prophylaxis">
          <h2>8. Infective Endocarditis Prophylaxis</h2>
          <div class="stack">
            <div class="box">
              <h3>Who Needs Prophylaxis?</h3>
              <ul>
                <li>Prosthetic valve patients</li>
                <li>Prior infective endocarditis</li>
                <li>Certain congenital heart diseases</li>
              </ul>
            </div>
            <div class="box">
              <h3>Procedure Context</h3>
              <ul>
                <li>Before high-risk dental procedures with gingival manipulation</li>
              </ul>
            </div>
            <div class="box">
              <h3>Amoxicillin (First-line)</h3>
              <ul>
                <li>MOA: beta-lactam, inhibits bacterial cell wall synthesis</li>
                <li>Use: prophylaxis in high-risk groups only</li>
                <li>Major side effects: hypersensitivity rash, GI upset</li>
                <li>Contraindication: serious beta-lactam allergy</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="management-recap-drill">
          <h2>Management Recap Drill</h2>
          <div class="flow">
            <div class="step"><strong>Aortic stenosis:</strong> valve replacement is definitive.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>Aortic regurgitation:</strong> afterload reduction support, surgery if symptomatic/LV dysfunction.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>Mitral regurgitation:</strong> repair preferred; ACE inhibitor plus diuretic support.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>Mitral stenosis:</strong> rate control and anticoagulate if AF present.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>Mechanical valve:</strong> warfarin only (no DOACs).</div>
          </div>

          <div class="diagram-card">
            <p class="diagram-title">Visual Algorithm Placeholder</p>
            <p>
              [Insert Valvular Disease Diagnostic and Treatment Flowchart Here During UI Integration]
            </p>
          </div>
        </section>

        <section class="section refs">
          <h2>Guideline References (Management)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>ACC/AHA Guideline: Valvular Heart Disease</h3>
              <a
                href="https://www.acc.org/guidelines"
                target="_blank"
                rel="noopener"
              >
                https://www.acc.org/guidelines
              </a>
            </div>
            <div class="box">
              <h3>High-Yield Scope</h3>
              <ul>
                <li>Timing of surgery/intervention</li>
                <li>TAVR candidacy principles</li>
                <li>Prosthetic valve anticoagulation</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="exam-traps">
          <h2>9. Common Exam Traps</h2>
          <div class="stack">
            <div class="callout alert">DOACs are contraindicated in mechanical valves.</div>
            <div class="callout alert">Severe AS: avoid aggressive vasodilation.</div>
            <div class="callout alert">MS with AF requires anticoagulation.</div>
            <div class="callout alert">SAD describes severe AS symptom triad.</div>
            <div class="callout alert">Definitive severe valve disease treatment is intervention, not medical therapy alone.</div>
          </div>
        </section>

        <section class="section" id="quick-revision">
          <h2>10. Quick Revision Summary</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Core Memory Anchors</h3>
              <ul>
                <li>AS: pressure overload</li>
                <li>AR: volume overload</li>
                <li>MR: left atrial dilation and AF tendency</li>
                <li>MS: often rheumatic</li>
                <li>Mechanical valves: lifelong warfarin</li>
              </ul>
            </div>
            <div class="box">
              <h3>Practice Questions Placeholder</h3>
              <ul>
                <li>Topic: Valvular Heart Disease</li>
                <li>
                  Subtopics: aortic stenosis, aortic regurgitation, mitral regurgitation, mitral stenosis, prosthetic valves, endocarditis prophylaxis
                </li>
              </ul>
            </div>
          </div>
        </section>
      </article>
    </div>
  </body>
</html>
